B-CULTUREoffers the BIOreACT system (figure 1) to the Pharma, Cosmetic and Medical Implants Industries as a solution for relevant preclinical product screening. Typically, drugs take 12 years to be licensed and the costs reach $1.5 billion^[1]. In average, 87% of the molecules getting to the clinical trials are false positives due to low preclinical testing accuracy^[2]. Notably, improving 10% in their prediction can save up $100 million/molecule^[3]. In this regard, B-CULTURE technology enables a human-like 4D environment able to control and regulate two different but connected human-like tissues (e.g. bone-cartilage, dermis-epidermis, blood-brain sides,), granting no ethical concerns unlike animal models and realistic screening unlike the in vitro alternatives. Our first products-to-market are the skin and osteochondral models. Overall, we provide a solution for monitored realistic screening of medical products.